Tonix Total Assets from 2010 to 2024

TNXP Stock

USD 0.19 0.01 5.00%

Tonix Pharmaceuticals Total Assets yearly trend continues to be relatively stable with very little volatility. Total Assets are likely to grow to about 162.2 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2008-03-31

Previous Quarter

70.3 M

Current Value

95 M

Quarterly Volatility

75.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Tonix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tonix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 9.6 M, Selling General Administrative of 36.5 M or Gross Profit of 3.2 M, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.44 or PTB Ratio of 0.0683. Tonix financial statements analysis is a perfect complement when working with Tonix Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Tonix Pharmaceuticals Correlation against competitors.

Latest Tonix Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Tonix Pharmaceuticals Holding over the last few years. Total assets refers to the total amount of Tonix Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tonix Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Tonix Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tonix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 154.46 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Tonix Total Assets Regression Statistics

	Arithmetic Mean	71,629,028
	Geometric Mean	19,659,485
	Coefficient Of Variation	116.83
	Mean Deviation	69,768,628
	Median	27,510,000
	Standard Deviation	83,682,922
	Sample Variance	7002.8T
	Range	240.9M
	R-Value	0.80
	Mean Square Error	2659.6T
	R-Squared	0.65
	Significance	0.0003
	Slope	15,055,210
	Total Sum of Squares	98039.6T

Tonix Total Assets History

	2024	162.2 M
	2023	154.5 M
	2022	225.7 M
	2021	240.9 M
	2020	98.2 M
	2019	14.6 M
	2018	26.3 M

Other Fundumenentals of Tonix Pharmaceuticals

Intangibles To Total Assets

Tonix Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Term Debt	Intangible Assets	Property Plant Equipment	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.94	-0.8	-0.84	0.83	0.23	0.73	0.89	0.69	0.88	0.94	0.69	0.68	-0.4	0.91	-0.22	0.5	0.43	0.83	-0.4	0.97	0.8	0.71
Total Stockholder Equity	0.94		-0.92	-0.68	0.85	0.25	0.49	0.96	0.75	0.94	0.8	0.7	0.56	-0.08	0.76	-0.18	0.22	0.14	0.65	-0.08	0.97	0.91	0.76
Net Debt	-0.8	-0.92		0.42	-0.74	-0.17	-0.2	-0.98	-0.86	-0.94	-0.57	-0.55	-0.42	-0.16	-0.55	0.17	0.07	0.16	-0.35	-0.16	-0.86	-0.97	-0.87
Retained Earnings	-0.84	-0.68	0.42		-0.61	-0.27	-0.91	-0.56	-0.36	-0.58	-0.94	-0.51	-0.82	0.69	-0.98	0.34	-0.81	-0.75	-0.93	0.69	-0.73	-0.4	-0.38
Net Receivables	0.83	0.85	-0.74	-0.61		0.13	0.53	0.81	0.69	0.79	0.74	0.82	0.54	-0.17	0.68	-0.18	0.32	0.24	0.62	-0.17	0.85	0.78	0.69
Short Term Investments	0.23	0.25	-0.17	-0.27	0.13		0.15	0.29	0.09	0.28	0.2	0.22	0.11	0.0	0.27	0.53	0.09	0.05	0.1	0.0	0.12	0.1	0.1
Total Liab	0.73	0.49	-0.2	-0.91	0.53	0.15		0.37	0.29	0.41	0.91	0.49	0.68	-0.88	0.89	-0.22	0.95	0.93	0.94	-0.88	0.6	0.23	0.3
Total Current Assets	0.89	0.96	-0.98	-0.56	0.81	0.29	0.37		0.86	0.97	0.7	0.63	0.5	0.0	0.68	-0.11	0.1	0.01	0.49	0.0	0.91	0.96	0.87
Common Stock	0.69	0.75	-0.86	-0.36	0.69	0.09	0.29	0.86		0.88	0.54	0.45	0.43	0.01	0.5	-0.22	0.06	-0.01	0.28	0.01	0.74	0.89	1.0
Accounts Payable	0.88	0.94	-0.94	-0.58	0.79	0.28	0.41	0.97	0.88		0.71	0.61	0.56	-0.03	0.69	-0.17	0.13	0.05	0.51	-0.03	0.91	0.94	0.89
Net Tangible Assets	0.94	0.8	-0.57	-0.94	0.74	0.2	0.91	0.7	0.54	0.71		0.64	0.72	-0.66	0.97	-0.24	0.75	0.7	0.95	-0.66	0.87	0.59	0.55
Current Deferred Revenue	0.69	0.7	-0.55	-0.51	0.82	0.22	0.49	0.63	0.45	0.61	0.64		0.27	-0.18	0.56	0.04	0.33	0.26	0.56	-0.18	0.67	0.55	0.44
Long Term Debt	0.68	0.56	-0.42	-0.82	0.54	0.11	0.68	0.5	0.43	0.56	0.72	0.27		-0.49	0.81	-0.48	0.57	0.52	0.69	-0.49	0.62	0.42	0.46
Long Term Debt Total	-0.4	-0.08	-0.16	0.69	-0.17	0.0	-0.88	0.0	0.01	-0.03	-0.66	-0.18	-0.49		-0.65	0.17	-0.94	-0.95	-0.76	1.0	-0.25	0.13	0.01
Capital Surpluse	0.91	0.76	-0.55	-0.98	0.68	0.27	0.89	0.68	0.5	0.69	0.97	0.56	0.81	-0.65		-0.31	0.75	0.69	0.91	-0.65	0.82	0.54	0.53
Deferred Long Term Liab	-0.22	-0.18	0.17	0.34	-0.18	0.53	-0.22	-0.11	-0.22	-0.17	-0.24	0.04	-0.48	0.17	-0.31		-0.2	-0.18	-0.29	0.17	-0.3	-0.23	-0.24
Short Term Debt	0.5	0.22	0.07	-0.81	0.32	0.09	0.95	0.1	0.06	0.13	0.75	0.33	0.57	-0.94	0.75	-0.2		0.99	0.83	-0.94	0.34	-0.05	0.07
Intangible Assets	0.43	0.14	0.16	-0.75	0.24	0.05	0.93	0.01	-0.01	0.05	0.7	0.26	0.52	-0.95	0.69	-0.18	0.99		0.8	-0.95	0.27	-0.13	-0.01
Property Plant Equipment	0.83	0.65	-0.35	-0.93	0.62	0.1	0.94	0.49	0.28	0.51	0.95	0.56	0.69	-0.76	0.91	-0.29	0.83	0.8		-0.76	0.75	0.38	0.3
Long Term Investments	-0.4	-0.08	-0.16	0.69	-0.17	0.0	-0.88	0.0	0.01	-0.03	-0.66	-0.18	-0.49	1.0	-0.65	0.17	-0.94	-0.95	-0.76		-0.25	0.13	0.01
Net Invested Capital	0.97	0.97	-0.86	-0.73	0.85	0.12	0.6	0.91	0.74	0.91	0.87	0.67	0.62	-0.25	0.82	-0.3	0.34	0.27	0.75	-0.25		0.89	0.76
Net Working Capital	0.8	0.91	-0.97	-0.4	0.78	0.1	0.23	0.96	0.89	0.94	0.59	0.55	0.42	0.13	0.54	-0.23	-0.05	-0.13	0.38	0.13	0.89		0.9
Capital Stock	0.71	0.76	-0.87	-0.38	0.69	0.1	0.3	0.87	1.0	0.89	0.55	0.44	0.46	0.01	0.53	-0.24	0.07	-0.01	0.3	0.01	0.76	0.9

Click cells to compare fundamentals

About Tonix Pharmaceuticals Financial Statements

Tonix Pharmaceuticals shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Tonix Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tonix Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tonix Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	154.5 M	162.2 M
Intangibles To Total Assets	0.07	0.07

Pair Trading with Tonix Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tonix Stock

0.61

VALN

Valneva SE ADR

Pair Corr

Moving against Tonix Stock

0.63

NXGLW

NexGel Warrant

Pair Corr

The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.

The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Tonix Stock Analysis

When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC